Advertisement
CellCyte Genetics is developing stem cell enabling therapeutic productsdesigned to allow more efficient delivery and significantly increasedretention of adult stem cells to diseased organs, such as the heart.
Advertisement
Along with its planned human trials for its therapeutics, CellCyteGenetics intends to develop a new stem cell cultivation device or "bioreactor"unit for which CellCyte Genetics owns the worldwide patent and rights. TheCompany plans to market the device for applications that will require cells tobe grown under regulated oxygen concentrations, e.g. the replication of stemcells and the culture of pancreatic islet cells prior to transplantation intodiabetic patients.
Dr. Ron Berninger, Chief Scientific Officer of CellCyte Genetics explains,"CellCyte's patented biological cell maintenance system has the unique abilityto incubate cultured cells with a very efficient and regulatable oxygensupply, making it an ideal choice for culturing cells that are otherwisedifficult to keep alive or to expand. Inside the bioreactor, the cells canalso form a 3-dimensional network, which is what most cell types do in majororgans of the body."
A key element of this bioreactor is the capability to supply oxygen (bybundles of oxygen fibers) to the cells throughout the entire space in whichcells are growing. Stem cells appear to be sensitive to oxygen levels and canbe induced to replicate or differentiate in part by controlling the oxygenlevel.
Using CellCyte's product, scientists, researchers and clinicians should beable to dramatically increase the number of stem cells available for researchand potentially for use in stem cell therapies. Management believes that thebioreactor unit will be the Company's first revenue producing research productand is expected be ready for market in 2008.
CellCyte Genetics acquired the patents and rights to the bioreactor unitand several other key technologies from the developer of the technology in2006 as part of its original Intellectual property portfolio. The Companybegan work on remolding key parts of the bioreactor for manufacturing earlierthis year as part of CellCyte's efforts to prepare for human trials and FDAapplication for the use of its stem cell therapies. With the manufacturingpath and contract suppliers now set, CellCyte has begun gearing up this DeviceDivision to complete development of the bioreactor and several othersynergistic technologies.
The Device Division will operate as a separate division of the Company andwill carry out R & D, manufacturing, and sales and marketing functions throughthe facilities of CellCyte Genetics' new facilities in Bothell near Seattle,Washington.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emergingbiotechnology company engaged in the principle business of the discovery,development and commercialization of breakthrough stem cell enablingtherapeutic products.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM ISDEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, ASAMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934,AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL,ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS,PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THEHISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWSRELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKSAND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROMANY FUTURE
